FindTrial
Sign In

A phase I, randomized, double-blind, placebo-controlled, two-way cross-over, multiple dose study to evaluate the pharmacodynamic effects of TRV045 on the cortical excitability in healthy male adults

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-502638-17-00
Acronym
CP045-1004
Enrollment
24
Registered
2023-01-31
Start date
2023-02-03
Completion date
2023-06-09
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

Change from baseline in Motor Evoked Potential: • Peak-to-peak amplitude (μV)

Interventions

DRUGTrv045 placebo

Sponsors

Trevena Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Change from baseline in Motor Evoked Potential: • Peak-to-peak amplitude (μV)—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026